Brief: Abionyx Pharma Reports Positive Interim Results From Phase 2a Trial Of CER-001 For Septic Patients At High Risk Of AKI

Abionyx Pharma SA

07/04/2022 06:40

April 7 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ABIONYX PHARMA REPORTS POSITIVE INTERIM RESULTS FROM PHASE
2A
CLINICAL TRIAL EVALUATING CER-001 IN THE TREATMENT OF SEPTIC
PATIENTS AT HIGH RISK OF DEVELOPING ACUTE KIDNEY INJURY
    * RAPID REVERSAL OF CYTOKINE STORM IN SEPTIC PATIENTS
    * ENHANCED RESOLUTION OF BIOMARKERS FOR INFLAMMATION
INCLUDING
LEUKOCYTOSIS COMPARED TO STANDARD OF CARE
    * NO TREATMENT-RELATED SERIOUS SIDE EFFECTS

Source text for Eikon:  ID:nBw6nGVyDa 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))